Dupixent's on a roll in eczema and asthma, but COPD's a ‘much tougher’ malady: Regeneron CEO

7th May 2019 Uncategorised 0

Armed with new nods in asthma and adolescent eczema, Sanofi and Regeneron’s Dupixent continues its upward march. But an upcoming phase 3 study that aims to tap into COPD could be “much tougher,” Regeneron CEO Len Schleifer said.

More: Dupixent's on a roll in eczema and asthma, but COPD's a ‘much tougher’ malady: Regeneron CEO
Source: fierce